Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk

American Journal of Epidemiology

Volumn 170, Issue 10, 2009, Pages 1241-1249

  Reding, Kerryn W ^a,b   Li, Christopher I ^a,b   Weiss, Noel S ^a,b   Chen, Chu ^a,b   Carlson, Christopher S ^a,b   Duggan, David ^c   Thummel, Kenneth E ^a   Daling, Janet R ^b   Malone, Kathleen E ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

Breast neoplasms; Hormone replacement therapy; Progesterone; Receptors, progesterone

Indexed keywords

CYTOCHROME P450 3A4; ESTROGEN; OXIDOREDUCTASE; PROGESTERONE; PROGESTERONE RECEPTOR; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2;

ALLELE; CANCER; GENETIC VARIATION; HEALTH RISK; HORMONE; METABOLISM; POLYMORPHISM; TEMPORAL ANALYSIS;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER HORMONE THERAPY; CANCER RISK; CONTROLLED STUDY; DRUG CARCINOGENICITY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HORMONAL REGULATION; HUMAN; MAJOR CLINICAL STUDY; PHARMACOGENOMICS; POPULATION RESEARCH; POSTMENOPAUSE; PROGESTERONE METABOLISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES;

3-HYDROXYSTEROID DEHYDROGENASES; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; ESTROGEN REPLACEMENT THERAPY; FEMALE; GENETIC VARIATION; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; HYDROXYSTEROID DEHYDROGENASES; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; RISK FACTORS; WASHINGTON;

NORTH AMERICA; UNITED STATES; WASHINGTON [UNITED STATES];

EID: 70350673957     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwp298     Document Type: Article

References (40)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative re-analysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347(9017):1713-1727.
2. Rossouw JE, Anderson GL, Prentice RL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
3. Daling JR, Malone KE, Doody DR, et al. Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years. Cancer Epidemiol Biomarkers Prev. 2003;12(11):1175- 1181.
4. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA. 2003;289(24):3254-3263.
5. Newcomer LM, Newcomb PA, Potter JD, et al. Postmeno-pausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control. 2003;14(3): 225-233.
6. Daling JR, Malone KE, Doody DR, et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer. 2002; 95(12):2455-2464.
7. Collins JA, Blake JM, Crosignani PG. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update. 2005;11(6):545-560.
8. Chen CL, Weiss NS, Newcomb P, et al. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287(6): 734-741.
9. Newcomb PA, Titus-Ernstoff L, Egan KM, et al. Postmeno-pausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11(7):593-600. (Pubitemid 34760816)
10. Olsson H, Bladström A, Ingvar C, et al. A population-based cohort study of HRT use and breast cancer in southern Sweden. Br J Cancer. 2001;85(5):674-677.
11. Kirsh V, Kreiger N. Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada. Cancer Causes Control. 2002;13(6):583-590.
12. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008;299(9):1036-1045.
13. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712.
14. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350(9084):1047-1059.
15. Ross RK, Paganini-Hill A, Wan PC, et al. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000;92(4):328-332.
16. Lewis MJ, Wiebe JP, Heathcote JG. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma [electronic article]. BMC Cancer. 2004;4:27.
17. Giangrande PH, Kimbrel EA, Edwards DP, et al. The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol. 2000;20(9):3102-3115.
18. Lange CA, Richer JK, Horwitz KB. Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol. 1999;13(6):829-836.
19. Hovland AR, Powell RL, Takimoto GS, et al. An N-terminal inhibitory function, IF, suppresses transcription by the A-isoform but not the B-isoform of human progesterone receptors. J Biol Chem. 1998;273(10):5455-5460.
20. Li X, Lonard DM, O'Malley BW. A contemporary understanding of progesterone receptor function. Mech Ageing Dev. 2004;125(10-11):669-678.
21. Skildum A, Faivre E, Lange CA. Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Mol Endocrinol. 2005;19(2):327-339.
22. Wiebe JP, Muzia D, Hu J, et al. The 4-pregnene and 5a-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. Cancer Res. 2000;60(4):936-943.
23. Wiebe JP, Lewis MJ. Activity and expression of progesterone metabolizing 5a-reductase, 20a-hydroxysteroid oxidoreduc-tase and 3a(b)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells [electronic article]. BMC Cancer. 2003;3:9.
24. Ji Q, Aoyama C, Nien YD, et al. Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling. Cancer Res. 2004;64(20):7610-7617.
25. Kobayashi K, Mimura N, Fujii H, et al. Role of human cyto-chrome P450 3A4 in metabolism of medroxyprogesterone acetate. Clin Cancer Res. 2000;6(8):3297-3303.
26. Hillman JJ, Zuckerman IH, Lee E. The impact of the Women's Health Initiative on hormone replacement therapy in a Med-icaid program. J Womens Health (Larchmt). 2004;13(9):986-992.
27. Li CI, Malone KE, Porter PL, et al. Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. Cancer Epidemiol Bio-markers Prev. 2008;17(1):43-50.
28. de Bakker PI, Yelensky R, Pe'er I, et al. Efficiency and power in genetic association studies. Nat Genet. 2005;37(11):1217-1223.
29. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68(4):978-989.
30. Wacholder S, Chanock S, Garcia-Closas M, et al. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004; 96(6):434-442. (Pubitemid 38443646)
31. Rebbeck TR, Troxel AB, Norman S, et al. Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk. Am J Epidemiol. 2007;166(12):1392-1399. (Pubitemid 350209049)
32. De Vivo I, Hankinson SE, Colditz GA, et al. A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk. Cancer Res. 2003;63(17): 5236-5238.
33. Diergaarde B, Potter JD, Jupe ER. Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(7):1751-1759.
34. Takahashi RH, Grigliatti TA, Reid RE, et al. The effect of allelic variation in aldo-keto reductase 1C2 on the in vitro metabolism of dihydrotestosterone. J Pharmacol Exp Ther. 2009;329(3):1032-1039.
35. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B. 1995;57(1):289-300.
36. Kastner P, Krust A, Turcotte B, et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 1990;9(5):1603-1614.
37. Pooley KA, Healey CS, Smith PL, et al. Association of the progesterone receptor gene with breast cancer risk: a single-nucleotide polymorphism tagging approach. Cancer Epidemiol Biomarkers Prev. 2006;15(4):675-682.
38. Feigelson HS, Rodriguez C, Jacobs EJ, et al. No association between the progesterone receptor gene 331G/A polymorphism and breast cancer. Cancer Epidemiol Biomarkers Prev. 2004;13(6):1084-1085.
39. Johnatty SE, Spurdle AB, Beesley J. Progesterone receptor polymorphisms and risk of breast cancer: results from two Australian breast cancer studies. Breast Cancer Res Treat. 2008;109(1):91-99.
40. Boudreau DM, Daling JR, Malone KE, et al. A validation study of patient interview data and pharmacy records for an-tihypertensive, statin, and antidepressant medication use among older women. Am J Epidemiol. 2004;159(3):308-317.